{"organizations": [], "uuid": "4852623202bb60713574e47eef477bf87e57fb52", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-celgene-says-bluebird-car-t-therap/brief-celgene-says-bluebird-car-t-therapy-remains-a-top-priority-idUSL2N1PK0UM", "country": "US", "domain_rank": 408, "title": "BRIEF-Celgene Says Bluebird Car-T Therapy Remains A Top Priority", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-25T17:02:00.000+02:00", "replies_count": 0, "uuid": "4852623202bb60713574e47eef477bf87e57fb52"}, "author": "", "url": "https://www.reuters.com/article/brief-celgene-says-bluebird-car-t-therap/brief-celgene-says-bluebird-car-t-therapy-remains-a-top-priority-idUSL2N1PK0UM", "ord_in_thread": 0, "title": "BRIEF-Celgene Says Bluebird Car-T Therapy Remains A Top Priority", "locations": [], "entities": {"persons": [{"name": "bill berkrot", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters staff", "sentiment": "none"}, {"name": "celgene corp", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "fedratinib", "sentiment": "none"}, {"name": "celgene", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 25, 2018 / 3:05 PM / in 23 minutes BRIEF-Celgene Says Bluebird Car-T Therapy Remains A Top Priority Reuters Staff 1 Min Read \nJan 25 (Reuters) - Celgene Corp: \n* CELGENE CEO SAYS WORKING WITH BLUEBIRD BIO TO DEVELOP BB2121 CAR-T THERAPY FOR MYELOMA REMAINS A TOP PRIORITY \n* CELGENE CEO SAYS POSITIONED TO LAUNCH TWO CAR-T THERAPIES IN BLOOD CANCERS IN NEXT 3 YEARS \n* CELGENE SEES $1 BILLION SALES POTENTIAL FOR FEDRATINIB IN MYELOFIBROSIS, MID-2018 REGULATORY SUBMISSION Source text for Eikon: Further company coverage: (Reporting By Bill Berkrot)", "external_links": [], "published": "2018-01-25T17:02:00.000+02:00", "crawled": "2018-01-25T17:35:58.003+02:00", "highlightTitle": ""}